The FDA has approved the use of a five-day, once-daily regimen of Levaquin (levofloxacin) 750 mg IV and oral for the treatment of complicated UTI and acute pyelonephritis (AP).

Acute graft pyelonephritis (AGPN) increases the risk of bacteremia, acute rejection, and cytomegalovirus (CMV) disease, but it does not independently contribute to poor graft or patient survival, researchers in India report.